LGG Probiotic for Allergic Rhinitis and Seasonal Allergies: What the Research Shows About Hay Fever, Birch Pollen, and the Hygiene Hypothesis (2026)

If you reach for antihistamines every spring or live with year-round congestion and sneezing, you have probably wondered whether changes inside the gut could quiet the immune reactions happening in your nose. The idea is not new. Researchers have been testing probiotics for allergic rhinitis for more than two decades, and Lactobacillus rhamnosus GG (LGG) sits at the center of much of that work. Some trials have been positive, others have been null. This article walks through what the published evidence actually shows about LGG and seasonal allergies, where the strongest signals are, and where the literature stops short of strong claims.

A Quick Summary

LGG is one of the most studied probiotic strains in the world, with research spanning gastrointestinal, immune, and atopic conditions. For allergic rhinitis specifically, the human trial picture is mixed. The earliest direct LGG trial in seasonal allergy (Helin 2002, birch pollen) did not show benefit on its primary outcomes. Later trials of LGG in perennial allergic rhinitis have reported quality-of-life improvements in some populations, particularly when given over longer periods. The broader probiotic literature, including meta-analyses, suggests that some probiotic strains can modestly improve symptom scores and quality of life in allergic rhinitis, but effects are not uniform across strains, populations, or allergens. Honest framing matters here: LGG is not a replacement for proven allergy care. It is a microbiome-support tool that some patients have found useful as part of a broader strategy.

What Allergic Rhinitis Actually Is

Allergic rhinitis is an IgE-mediated inflammation of the nasal mucosa triggered by inhaled allergens such as pollen, dust mites, mold, or animal dander. It can be seasonal (often called hay fever, driven by tree, grass, or weed pollens) or perennial (year-round, often driven by dust mites or indoor allergens). Symptoms typically include sneezing, nasal itching, runny nose, congestion, and itchy or watery eyes. The condition affects roughly 10 to 30 percent of adults and up to 40 percent of children globally, with prevalence rising steadily across recent decades [Brożek 2017 PMID 28602936; Bousquet 2019 PMID 31516692].

At the cellular level, allergic rhinitis involves Th2-skewed adaptive immunity, IgE production against innocuous environmental proteins, mast cell degranulation in the nasal mucosa, and release of histamine and other mediators. Modern allergy care focuses on allergen avoidance, antihistamines, intranasal corticosteroids, leukotriene antagonists, and, where appropriate, allergen-specific immunotherapy.

The Hygiene Hypothesis and Where Probiotics Fit

The link between gut bacteria and allergic disease comes from an observation made decades ago. In 1989, David Strachan published the original "hygiene hypothesis" in BMJ, observing that British children from larger families with more older siblings had less hay fever and eczema, possibly because earlier childhood infections shaped immune development [Strachan 1989 PMID 2513902]. The framework has evolved. Researchers now talk about the "old friends" hypothesis and the broader role of the gut microbiome in calibrating immune tolerance. Disruption of early-life microbial exposures, particularly during the window when adaptive immunity is being trained, appears to push immune development toward atopic patterns.

This is why probiotics entered allergy research. If gut microbes help train immune tolerance, the thinking goes, supplementing specific strains could shift the immune response away from the Th2-skewed pattern that drives allergic disease. LGG was one of the first strains tested because of its well-characterized safety profile and its ability to survive gastric transit and colonize the gut [Goldin 1992 PMID 1728516].

The First LGG Trial in Seasonal Allergy: Helin 2002

The earliest randomized controlled trial of LGG for seasonal allergy was published in 2002 in the journal Allergy by Helin and colleagues at Skin and Allergy Hospital in Helsinki. The trial enrolled 36 adults with birch pollen allergy and randomized them to receive LGG (5 x 10^9 CFU twice daily) or placebo for five and a half months covering the birch pollen season. Outcomes included nasal symptoms, quality of life, and immunological markers [Helin 2002 PMID 11906339].

The honest result: LGG did not significantly reduce symptoms or improve quality of life compared with placebo in the primary analysis. Immunological markers including serum IgE and cytokine responses were also not significantly different between groups. The authors concluded that LGG given during birch pollen season did not provide clinical benefit in this population at this dose. This was a small, single-allergen trial, but it set the tone for cautious interpretation of LGG in seasonal allergy.

Later Trials in Perennial Allergic Rhinitis

The picture has been somewhat more encouraging in perennial allergic rhinitis, particularly when LGG is combined with other strains or given over longer periods.

A trial by Wang and colleagues studied a live L. paracasei product in children with perennial allergic rhinitis and reported symptom and quality-of-life improvements [Wang 2004 PMID 15059192]. While not LGG, this opened the door to further research in perennial AR.

Costa and colleagues published a randomized double-blind placebo-controlled trial of L. paracasei in adults with persistent allergic rhinitis to grass pollen in 2014, reporting modest improvements in quality of life [Costa 2014 PMID 24569538]. A systematic review of randomized controlled trials published in 2008 by Vliagoftis and colleagues found that probiotic interventions for allergic rhinitis showed a modest but statistically significant benefit on quality of life, with mixed results for symptom scores [Vliagoftis 2008 PMID 19119700].

A 2015 systematic review by Zajac and colleagues in International Forum of Allergy and Rhinology examined 23 trials and concluded that probiotic supplementation, including LGG-containing formulations, was associated with improvements in disease-specific quality of life in allergic rhinitis patients compared with placebo, though heterogeneity between trials was substantial [Zajac 2015 PMID 25899251].

A more recent systematic review and meta-analysis by Luo and colleagues published in 2022 reviewed 28 studies of probiotics in allergic rhinitis and reported significant improvements in nasal symptom scores and quality of life with probiotic supplementation, while noting high heterogeneity between trials [Luo 2022 PMID 35663980].

LGG and Atopic March: The Childhood Window

LGG has been studied more extensively in the prevention of atopic disease in children at high risk of allergy, work largely pioneered by the Kalliomäki group in Finland. The original 2001 trial gave LGG prenatally to mothers with atopic family history and postnatally to their infants for six months, and reported significantly reduced atopic eczema at age 2 [Kalliomäki 2001 PMID 11297958]. Follow-up at age 4 maintained the eczema benefit [Kalliomäki 2003 PMID 12788576]. Follow-up at age 7 continued to show eczema benefit, while data on respiratory atopy outcomes (allergic rhinitis and asthma) at that age were less conclusive [Kalliomäki 2007 PMID 17289135].

This is an important point for adults considering LGG for hay fever. The strongest LGG-and-allergy evidence is in atopic eczema prevention in high-risk infants, not in adult allergic rhinitis. Whether the gut-immune training that supports eczema prevention translates to rhinitis prevention or treatment in adults remains uncertain.

Mechanisms: How LGG Could Influence Allergic Inflammation

The proposed mechanisms by which LGG might modulate allergic disease have been characterized in cell and animal models more thoroughly than in clinical trials. Several pathways have been described.

Certain lactobacilli have been shown to influence dendritic cell maturation in directions that favor immune tolerance rather than allergic sensitization, although LGG itself was not the strain studied in the original dendritic cell work [Smits 2005 PMID 15940144]. LGG and its bacterial surface components have been characterized in detail for their interactions with intestinal epithelium and mucosal immune cells [Lebeer 2008 PMID 19052326].

LGG can modulate the broader gut microbial community, which has been linked to systemic immune regulation. The gut-lung and gut-airway axes are active areas of research, with growing evidence that gut microbial signals reach mucosal immune sites throughout the body [Budden 2017 PMID 27694885].

These mechanistic findings are biologically plausible. They do not, on their own, mean clinical benefit. The gap between mechanism and clinical outcome is one of the harder lessons of probiotic research.

What the Research Does Not Show

It is worth being explicit about the limits of the current evidence base.

LGG monotherapy has not been shown to reliably reduce symptoms of seasonal allergic rhinitis at the dose and duration tested in Helin 2002. Larger and longer trials specifically targeting LGG in adult seasonal allergy populations have not been published. Meta-analyses that include multiple probiotic strains cannot be interpreted as supporting LGG specifically; they reflect a heterogeneous mix of strains, doses, and populations.

LGG does not replace antihistamines, intranasal corticosteroids, or allergen-specific immunotherapy. There is no high-quality evidence that LGG can prevent acute allergic reactions or reduce the need for established allergy medications. Anyone with significant allergic disease should remain under the care of an allergist or primary-care physician.

Practical Considerations

If you are interested in LGG as part of a broader gut-health approach during allergy season, a few points from the published trials are worth knowing.

Dose. Most positive probiotic-and-rhinitis trials have used doses in the range of 1 to 10 billion CFU per day. LGG has been studied at 10^9 to 10^10 CFU daily across various indications [Goldin 1992 PMID 1728516].

Duration. Meta-analytic data suggest probiotic supplementation can improve rhinitis quality of life, though heterogeneity between trials is substantial [Luo 2022 PMID 35663980]. For seasonal allergy, the practical implication is that starting a probiotic well before the pollen season is more biologically plausible than reaching for one on the day symptoms start.

Strain identity. LGG is a specific strain. Many products labeled "L. rhamnosus" use different strains with different characteristics. The strain designation GG, deposited as ATCC 53103, is what was studied in the trials cited above.

Realistic expectations. The published effect sizes for probiotics in allergic rhinitis, where they exist, are modest. Some patients report subjective improvements; others do not. LGG is not a substitute for proven allergy care.

Where LGG Fits

LGG is a well-studied probiotic strain with a strong safety record and decades of human research across gastrointestinal, immune, and atopic conditions. For allergic rhinitis specifically, the direct LGG evidence is limited and the seasonal-allergy evidence (Helin 2002) was null. Broader probiotic meta-analyses suggest modest benefit on rhinitis quality of life with sustained use of various strains. The strongest LGG-and-allergy data are in eczema prevention in at-risk infants, not adult hay fever.

For readers thinking about a daily probiotic as part of a long-term gut and immune-support routine, LGG remains one of the most credentialed strains available. For acute hay fever symptoms or moderate-to-severe allergic rhinitis, the published evidence does not support LGG as a primary intervention. Talk with your physician before adding any new supplement, particularly if you are immunocompromised, have a central venous catheter, or are taking immunosuppressive medications.

Wise Choice LGG Probiotic

Wise Choice Supplements offers a Lactobacillus rhamnosus GG (LGG) probiotic at 30 billion CFU per capsule, 90 capsules per bottle, in delayed-release format designed to support survival through gastric transit. It is the same strain (ATCC 53103) used in the human research cited throughout this article. If you would like to explore LGG as part of a broader gut-microbiome support routine, you can find it here.

Sources

• Brożek JL et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017. PMID 28602936
• Bousquet J et al. Next-generation ARIA care pathways for rhinitis and asthma. Clin Transl Allergy. 2019. PMID 31516692
• Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989. PMID 2513902
• Goldin BR et al. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992. PMID 1728516
• Helin T et al. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy. Allergy. 2002. PMID 11906339
• Wang MF et al. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol. 2004. PMID 15059192
• Costa DJ et al. Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study). Eur J Clin Nutr. 2014. PMID 24569538
• Vliagoftis H et al. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008. PMID 19119700
• Zajac AE et al. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. Int Forum Allergy Rhinol. 2015. PMID 25899251
• Luo C et al. The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol. 2022. PMID 35663980
• Kalliomäki M et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001. PMID 11297958
• Kalliomäki M et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003. PMID 12788576
• Kalliomäki M et al. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007. PMID 17289135
• Smits HH et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005. PMID 15940144
• Lebeer S et al. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev. 2008. PMID 19052326
• Budden KF et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017. PMID 27694885